DVAX David F Novack sells $471K worth of shares
Mar 11, 2025, 4:31 AM
0.00%
What does DVAX do
Dynavax Technologies is a biopharmaceutical company based in Emeryville, California, specializing in vaccines and immuno-oncology therapeutics, including the HEPLISAV-B hepatitis B vaccine. The company is developing additional vaccines, including candidates for shingles and Tdap.
David F Novack sold 32,764 shares of DVAX on 7 March at $14.39 per share, worth a total of $471K. They now own 22,098 DVAX shares, or a 60% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.